Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
Pharmacology, Toxicology and Pharmaceutical Science
2
2%
Nursing and Health Professions
2
2%
Neuroscience
2
2%
Other
7
8%
Unknown
44
49%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 63. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 September 2026.
All research outputs
#864,733
of 34,492,055 outputs
Outputs from Journal of Clinical Oncology
#2,103
of 32,547 outputs
Outputs of similar age
#16,268
of 466,772 outputs
Outputs of similar age from Journal of Clinical Oncology
#31
of 184 outputs
Altmetric has tracked 34,492,055 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 32,547 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.5. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 466,772 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 184 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.
